Concourse Financial Group Securities, Inc. Inhibikase Therapeutics, Inc. Transaction History

Concourse Financial Group Securities, Inc.

$1.64 Billion
Q3 2024

10 transactions

Quarter	Operation	Price Per share
Q1 2023 May 15, 2023	BUY	$0.54 - $0.91 $0 - $0
Q4 2022 Jan 30, 2023	BUY	$0.45 - $5.41 $0 - $0
Q3 2022 Nov 15, 2022	BUY	$0.76 - $5.46 $0 - $0
Q2 2022 Aug 09, 2022	BUY	$0.63 - $1.44 $0 - $0
Q1 2022 May 09, 2022	BUY	$1.03 - $1.77 $0 - $0
Q4 2021 Feb 07, 2022	BUY	$1.38 - $2.17 $0 - $0
Q3 2021 Nov 09, 2021	BUY	$1.79 - $2.81 $0 - $0
Q2 2021 Aug 13, 2021	BUY	$2.8 - $6.23 $0 - $0
Q1 2021 May 13, 2021	BUY	$5.2 - $7.95 $0 - $0
Q4 2020 Feb 02, 2021	BUY	$6.9 - $9.9 $0 - $0

Others Institutions Holding IKT

# of Institutions

Shares Held

1.03M

Call Options Held

Put Options Held

Act Capital Management, LLC Wayne, PA

938K
Shares

$1.88 Million
1.18% of portfolio
Zeke Capital Advisors, LLC Berwyn, PA

93.8K
Shares

$187,600
0.0% of portfolio

View Full List

About Inhibikase Therapeutics, Inc.

Ticker IKT
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 25,227,100
Market Cap $50.5M
Description
Inhibikase Therapeutics, Inc., a clinical stage pharmaceutical company, develops therapeutics for Parkinson's Disease (PD) and related disorders that arise inside and outside of the brain. The company's product candidates include IkT-148009, a small molecule Abelson tyrosine kinase inhibitor for use in the treatment of PD, as well as gastrointes...

More about IKT

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Concourse Financial Group Securities, Inc., based on Form 13F filings with the SEC.

News

Stay updated on Concourse Financial Group Securities, Inc. with notifications on news.

Account